|
|
|
| Clinical efficacy of Aidi Injection combined with VAD chemotherapy program in patients with multiple myeloma |
| TANG Hongxia1 WANG Mengying2 TUO Jing1 CUI Yisen1 WEN Jianwei1 |
1.Department of Hematology, Neijiang Traditional Chinese Medicine Hospital, Sichuan Province, Neijiang 641000, China;
2.Department of Cardiology, Chengdu First People′s Hospital, Sichuan Province, Chengdu 610016, China |
|
|
|
Abstract Objective To study the clinical efficacy and safety of Aidi Injection combined with VAD chemotherapy program in patients with multiple myeloma (MM). Methods A total of 60 patients with MM admitted to Neijiang Traditional Chinese Medicine Hospital of Sichuan Province from January 2015 to January 2018 were enrolled in this study. The subjects were divided into the control group and the treatment group according to the random number table method, with 30 cases in each group. The control group was treated with VAD chemotherapy program, the treatment group was treated with Aidi Injection combined with VAD chemotherapy program. Four weeks were a course of treatment, the two groups were treated for 3 courses. The clinical efficacy of the two groups were evaluated and compared. The serum M protein, β2-microglobulin, hemoglobin, myeloma cells and peripheral blood CD3+,CD4+,CD8+of the two groups before and after treatment were compared. The adverse reactions of the two groups during the treatment were recorded and compared. Results The total effective rate of the treatment group was higher than that of the control group, the difference was statistically significant (P ＜ 0.05). After treatment, the M protein, β2-microglobulin and the content of myeloma cells of the two groups were significantly less than those before treatment (P ＜ 0.05), the hemoglobin content was significantly greater than those before treatment (P ＜ 0.05), and the changes in the treatment group were significantly greater than those in the control group (P ＜ 0.05). After treatment, the levels of CD3+, CD4+ in peripheral blood of the treatment group were significantly higher than those before treatment (P ＜ 0.05), while the level of CD8+ in peripheral blood of the treatment group was significantly lower than that before treatment (P ＜ 0.05), and the levels of CD3+, CD4+ in peripheral blood of the treatment group were significantly higher than those of control group, while the level of CD8+ in peripheral blood of the treatment group was significantly lower than that of control group (P ＜ 0.05). There was no significant difference of the adverse reactions between the two groups during the treatment (P ＞ 0.05). Conclusion Aidi Injection combined with VAD chemotherapy program in patients with MM has good efficacy and safety, which can also improve the immune function of patients. It is worthy of clinical promotion and application.
|
|
|
|
|
|
[1] 孙雪娇，张翠红，王谦.多发性骨髓瘤治疗进展[J].继续医学教育，2018，32（4）：107-109.
[2] 王舒，关红梅.不同化疗方案治疗多发性骨髓瘤患者的效果比较[J].中国实验血液学杂志，2017，25（2）：485-489.
[3] 杜悦欣，袁婧，裴永强，等.VAD方案与MPT方案治疗老年多发性骨髓瘤的体会[J].临床医药文献电子杂志，2016， 3（26）：5191-5192.
[4] 冯建东.艾迪注射液在多发性骨髓瘤治疗中的临床价值分析[J].实用临床医药杂志，2013，17（19）：104-106.
[5] 胡婷，陈小萍，彭丽萍，等.艾迪注射液联合TAD方案治疗多发性骨髓瘤30例[J].中国中医药现代远程教育，2015， 13（20）：59-60.
[6] 中国医师协会血液科医师分会，中华医学会血液学分会，中国多发性骨髓瘤工作组.中国多发性骨髓瘤诊治指南（2013年修订）[J].中华内科杂志，2013，52（9）：791-795.
[7] 张之南，沈涕.血液病诊断及疗效标准[M].2版.北京：科学出版社，1998：373-380.
[8] 关晶，付蓉，阮二宝，等.多发性骨髓瘤患者骨病发病及其相关因素研究[J].中国肺癌杂志，2009，12（6）：655-656.
[9] 张艳，王忱，曹志刚.多发性骨髓瘤的X线、CT及MRI临床表现研究[J].中国CT和MRI杂志，2014，12（9）：113-115.
[10] 杨蕊雪，高露，施菊妹.多发性骨髓瘤的诊断进展与分期[J].中国癌症杂志，2014，24（10）：727-731.
[11] 赵霞，丁慧芳，刘娟，等.DC-CIK免疫治疗联合化疗对多发性骨髓瘤患者T细胞分泌细胞因子的影响[J].中国实验血液学杂志，2015，23（6）：1633-1637.
[12] 孙宁，于文晓，袁芳.VAD方案联合艾迪注射液治疗多发性骨髓瘤的临床疗效及对骨髓浆细胞数量、T淋巴细胞群的影响[J].河北中医，2018，40（5）：717-733.
[13] 徐洁，居文政，谈恒山.艾迪注射液药理作用及临床应用研究概况[J].药学与临床研究，2012，20（1）：48-52.
[14] 王爽，郑秀艳，孙文华，等.艾迪注射液与沙利度胺对老年多发性骨髓瘤患者血清APRIL、β2-m和TPO水平的影响[J].现代生物医学进展，2015，15（31）：6078-6081.
[15] 罗卓卡，张明珠，何丽霞，等.抗肿瘤辅助药艾迪注射液的应用现状及合理性分析[J].安徽医药，2016，20（1）：191-192.
[16] 刘宪凯，吕国庆，杨满，等.来那度胺、三氧化二砷及维生素C治疗复发/难治性多发性骨髓瘤的疗效分析[J].中国现代医生，2018，56（2）：16-19.
[17] 胡婷，彭丽萍，张琛晓，等.胸腺五肽联合化疗对多发性骨髓瘤患者外周血T淋巴细胞亚群的影响[J].中国当代医药，2018，25（5）：74-76.
[18] 石希均.艾迪注射液联合VAD方案治疗多发性骨髓瘤疗效分析[J].中国医药指南，2011，9（10）：21-22.
[19] 宋斌，万楚成，李章志，等.艾迪注射液联合VAD方案治疗老年多发性骨髓瘤的临床研究[J].中国医药导报，2012，9（7）：69-80.
[20] 初晓丽，李铎.低剂量沙利度胺联合常规化疗治疗多发性骨髓瘤的临床疗效[J].中国现代医生，2016，54（34）：73-75.
[21] 吴楠，霍聪，常赫，等.补肾化瘀法联合沙利度胺治疗多发性骨髓瘤的临床疗效研究[J].世界中医药，2017，12（1）：104-108.
[22] 颜斌，魏锦，陈健，等.多发性骨髓瘤患者外周血T细胞亚群及细胞免疫功能研究[J].重庆医学，2013，42（11）：1210-1212.
[23] 魏占杰.补肾养骨汤联合VAD方案对老年多发性骨髓瘤血清IL-6和VEGF水平的影响[J].西部中医药，2017， 30（5）：88-91.
[24] 林志娟，骆宜茗.小剂量沙利度胺联合VED化疗方案治疗老年初发多发性骨髓瘤的临床效果[J].中国当代医药，2016，23（36）：63-65，72.
[25] 罗文丰，邹兴立，杨竹.流式细胞术检测多发性骨髓瘤中骨髓细胞表面免疫表型的价值[J].中国肿瘤临床与康复，2017，24（8）：957-959.
[26] 赵继伟，洪少杰.57例中青年多发性骨髓瘤的临床特点[J].现代医院，2018，18（2）：264-267.
[27] 陈雁，宋斌，胡平，等.艾迪注射液联合化疗治疗多发性骨髓瘤的疗效及其对免疫功能的影响[J].现代肿瘤医学，2017，25（24）：4066-4068. |
|
|
|
